Next report date
Report period
Q4 2023
EPS estimate
−0.70USD
Revenue estimate
—
−3.14USD
−92.91 MUSD
29.97 M
About KalVista Pharmaceuticals, Inc.
Sector
CEO
Benjamin L. Palleiko
Headquarters
Cambridge
Website
Employees (FY)
118
Founded
2004
FIGI
BBG0026ZG5B0
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of KALV is 10.78 USD — it has increased by 2.76% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange KalVista Pharmaceuticals, Inc. stocks are traded under the ticker KALV.
KalVista Pharmaceuticals, Inc. is going to release the next earnings report on Jul 5, 2024. Keep track of upcoming events with our Earnings Calendar.
KALV stock is 5.36% volatile and has beta coefficient of 0.98. Check out the list of the most volatile stocks — is KalVista Pharmaceuticals, Inc. there?
KALV earnings for the last quarter are −0.80 USD per share, whereas the estimation was −0.76 USD resulting in a −4.92% surprise. The estimated earnings for the next quarter are −0.75 USD per share. See more details about KalVista Pharmaceuticals, Inc. earnings.
Yes, you can track KalVista Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
KALV stock has fallen by 5.60% compared to the previous week, the month change is a 3.75% fall, over the last year KalVista Pharmaceuticals, Inc. has showed a 34.25% increase.
KALV net income for the last quarter is −29.03 M USD, while the quarter before that showed −27.65 M USD of net income which accounts for −4.98% change. Track more KalVista Pharmaceuticals, Inc. financial stats to get the full picture.
Today KalVista Pharmaceuticals, Inc. has the market capitalization of 454.79 M, it has decreased by 3.70% over the last week.
No, KALV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, KALV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KalVista Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 118.00 employees. See our rating of the largest employees — is KalVista Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KalVista Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KalVista Pharmaceuticals, Inc. stock shows the sell signal. See more of KalVista Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on KalVista Pharmaceuticals, Inc. future price: according to them, KALV price has a max estimate of 39.00 USD and a min estimate of 20.00 USD. Read a more detailed KalVista Pharmaceuticals, Inc. forecast: see what analysts think of KalVista Pharmaceuticals, Inc. and suggest that you do with its stocks.